慢性肾脏病患者血管钙化的机制研究

doi:10.19586/j.2095-2341.2025.0084

生物技术进展 ›› 2025, Vol. 15 ›› Issue (5): 828-838.DOI: 10.19586/j.2095-2341.2025.0084

慢性肾脏病患者血管钙化的机制研究

李海芳¹(), 朱艳华²()

^1.湖北省阳新县人民医院肝胆外科，湖北黄石 435200
^2.湖北省阳新县人民医院神经内科，湖北黄石 435200

收稿日期:2025-07-15 接受日期:2025-09-05 出版日期:2025-09-25 发布日期:2025-11-11
通讯作者: 朱艳华
作者简介:李海芳 E-mail: 270276145@qq.com；

Mechanistic Insights into Vascular Calcification in Chronic Kidney Disease Patients

Haifang LI¹(), Yanhua ZHU²()

^1.Department of Hepatobiliary Surgery，Yangxin County People's Hospital，Hubei Huangshi 435200，China
^2.Department of Neurology，Yangxin County People's Hospital，Hubei Huangshi 435200，China

Received:2025-07-15 Accepted:2025-09-05 Online:2025-09-25 Published:2025-11-11
Contact: Yanhua ZHU

摘要/Abstract

摘要：

慢性肾脏病（chronic kidney disease, CKD）患者常发生血管钙化（vascular calcification, VC），这是导致其心血管疾病（cardiovascular disease,CVD）高发的主要原因。血管平滑肌细胞（vascular smooth muscle cells, VSMC）向成骨样细胞的转分化是VC的核心环节，受高磷血症、炎症及尿毒症毒素等复杂因素调控，但其精确分子机制尚不明确。综述了CKD背景下VC的病理机制，重点探讨了VSMC成骨样表型转化等VC的核心机制。血管钙化的发生发展受到表观遗传、细胞应激、细胞衰老等多层次的调控，这些改变相互影响，共同构成了血管钙化进展的关键驱动因素。深入阐明VSMC表型转化的分子机制，不仅可为CKD相关VC提供精准治疗靶点，还能为开发新型干预手段奠定理论基础，最终改善患者心血管疾病预后和生存质量。

关键词: 慢性肾脏病, 血管钙化, 血管平滑肌细胞, 成骨样转分化

Abstract:

Vascular calcification （VC） is a prevalent complication in patients with chronic kidney disease （CKD） and a major contributor to their high cardiovascular disease （CVD）. A central event in VC is the transdifferentiation of vascular smooth muscle cells （VSMC） into an osteoblast-like phenotype. This process is driven by complex factors including hyperphosphatemia， inflammation， and uremic toxins. However， its precise molecular mechanisms remain elusive. This review summarized the pathological mechanisms of VC in the context of CKD， focusing on the osteogenic phenotypic transformation of VSMC. Furthermore， the pathogenesis of VC involves epigenetic modifications， cellular stress， and senescence. These alterations interact and collectively drive disease progression. A deeper understanding of the molecular mechanisms underlying VSMC phenotypic transformation is crucial， as it will not only identify precise therapeutic targets for CKD-related VC but also lay a theoretical foundation for developing novel interventions， with the ultimate goal of improving patients' cardiovascular outcomes and quality of life.

Key words: chronic kidney disease, vascular calcification, vascular smooth muscle cells, osteoblast-like transition

中图分类号:

Q954.56+1

李海芳, 朱艳华. 慢性肾脏病患者血管钙化的机制研究[J]. 生物技术进展, 2025, 15(5): 828-838.

Haifang LI, Yanhua ZHU. Mechanistic Insights into Vascular Calcification in Chronic Kidney Disease Patients[J]. Current Biotechnology, 2025, 15(5): 828-838.

图/表 2

参考文献 120

[1]	JIANG Y, TUAN R S. Role of NGF-TrkA signaling in calcification of articular chondrocytes[J]. FASEB J., 2019, 33(9): 10231-10239.
[2]	SARNAK M J, AMANN K, BANGALORE S, et al.. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review[J]. J. Am. Coll. Cardiol., 2019, 74(14): 1823-1838.
[3]	THOMAS B, MATSUSHITA K, ABATE K H, et al.. Global cardiovascular and renal outcomes of reduced GFR[J]. J. Am. Soc. Nephrol., 2017, 28(7): 2167-2179.
[4]	LU Y, MENG L, REN R, et al.. Paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription[J]. Kidney Int., 2024, 105(6): 1221-1238.
[5]	LANZER P, BOEHM M, SORRIBAS V, et al.. Medial vascular calcification revisited: review and perspectives[J]. Eur. Heart J., 2014, 35(23): 1515-1525.
[6]	方学升,包明威.骨膜蛋白在心血管疾病中的研究进展[J].生物技术进展,2023,13(5):725-729.
	FANG X S, BAO M W. Research advances of POSTN in cardiovascular diseases[J]. Curr. Biotechnol., 2023, 13(5): 725-729.
[7]	SHANAHAN C M. Mechanisms of vascular calcification in CKD-evidence for premature ageing?[J]. Nat. Rev. Nephrol., 2013, 9(11): 661-670.
[8]	RAGGI P. Cardiovascular disease: coronary artery calcification predicts risk of CVD in patients with CKD[J]. Nat. Rev. Nephrol., 2017, 13(6): 324-326.
[9]	LACOLLEY P, REGNAULT V, NICOLETTI A, et al.. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles[J]. Cardiovasc. Res., 2012, 95(2): 194-204.
[10]	CHEN Y, ZHAO X, WU H. Transcriptional programming in arteriosclerotic disease: a multifaceted function of the Runx2 (runt-related transcription factor 2)[J]. Arterioscler. Thromb. Vasc. Biol., 2021, 41(1): 20-34.
[11]	CHAVKIN N W, CHIA J J, CROUTHAMEL M H, et al.. Phosphate uptake-independent signaling functions of the type Ⅲ sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells[J]. Exp. Cell Res., 2015, 333(1): 39-48.
[12]	VOELKL J, LANG F, UECKARDT K, et al.. Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia[J]. Cell. Mol. Life Sci., 2019, 76(11): 2077-2091.
[13]	JOHNSON R C, LEOPOLD J A, LOSCALZO J. Vascular calcification: pathobiological mechanisms and clinical implications[J]. Circ. Res., 2006, 99(10): 1044-1059.
[14]	GOETTSCH C, HUTCHESON J D, AIKAWA M, et al.. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles[J]. J. Clin. Invest., 2016, 126(4): 1323-1336.
[15]	ZHANG X, LI Y, YANG P, et al.. Trimethylamine-N-oxide promotes vascular calcification through activation of NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome and NF-κB (nuclear factor κB) signals[J]. Arterioscler. Thromb. Vasc. Biol., 2020, 40(3): 751-765.
[16]	KANG J H, KAWANO T, MURATA M, et al.. Vascular calcification and cellular signaling pathways as potential therapeutic targets[J/OL]. Life Sci., 2024, 336: 122309[2025-07-15]. .
[17]	BEAZLEY K E, NURMINSKY D, LIMA F, et al.. Wnt16 attenuates TGFβ-induced chondrogenic transformation in vascular smooth muscle[J]. Arterioscler. Thromb. Vasc. Biol., 2015, 35(3): 573-579.
[18]	LIBERMAN M, JOHNSON R C, HANDY D E, et al.. Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification[J]. Biochem. Biophys. Res. Commun., 2011, 413(3): 436-441.
[19]	KIM W J, SHIN H L, KIM B S, et al.. RUNX2-modifying enzymes: therapeutic targets for bone diseases[J]. Exp. Mol. Med., 2020, 52(8): 1178-1184.
[20]	ZHONG H, YU H, CHEN J, et al.. The short-chain fatty acid butyrate accelerates vascular calcification via regulation of histone deacetylases and NF-κB signaling[J/OL]. Vascul. Pharmacol., 2022, 146: 107096[2025-07-15]. .
[21]	LIN M E, CHEN T, LEAF E M, et al.. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice[J]. Am. J. Pathol., 2015, 185(7): 1958-1969.
[22]	LINO M, WAN M H, ROCCA A S, et al.. Diabetic vascular calcification mediated by the collagen receptor discoidin domain receptor 1 via the phosphoinositide 3-kinase/Akt/runt-related transcription factor 2 signaling axis[J]. Arterioscler. Thromb. Vasc. Biol., 2018, 38(8): 1878-1889.
[23]	ZHU Y, MA W Q, HAN X Q, et al.. Advanced glycation end products accelerate calcification in VSMCs through HIF-1α/PDK4 activation and suppress glucose metabolism[J/OL]. Sci. Rep., 2018, 8: 13730[2025-07-15]. .
[24]	DURHAM A L, SPEER M Y, SCATENA M, et al.. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness[J]. Cardiovasc. Res., 2018, 114(4): 590-600.
[25]	OPDEBEECK B, MAUDSLEY S, AZMI A, et al.. Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance[J]. J. Am. Soc. Nephrol., 2019, 30(5): 751-766.
[26]	SHI J, YANG Y, WANG Y N, et al.. Oxidative phosphorylation promotes vascular calcification in chronic kidney disease[J/OL]. Cell Death Dis., 2022, 13(3): 229[2025-07-15]. .
[27]	LEE S J, LEE I K, HJEON J. Vascular calcification-new insights into its mechanism[J/OL]. Int. J. Mol. Sci., 2020, 21(8): 2685[2025-07-15]. .
[28]	ZHANG Z, WANG X, HUANG C, et al.. Size-dependent interactions between calciprotein particles and vascular endothelium[J/OL]. Mater. Today Bio., 2025, 31: 101599[2025-07-15]. .
[29]	ZHOU Z, DONG B, HE D, et al.. GLS1-mediated redundancy in glutamate accelerates arterial calcification via activating NMDAR/Ca(2+)/β-catenin pathway[J/OL]. Adv. Sci., 2025, 12(21): e2414252[2025-07-15]. .
[30]	LAN Z, LIANG Q, LI L, et al.. TRIM16 mediates K63-linked ubiquitination of DAB2 to facilitate vascular calcification[J]. Circ. Res., 2025, 137(4): 551-568.
[31]	LI Y, JIE W, QI Y, et al.. Inhibition of RIPK1 alleviating vascular smooth muscle cells osteogenic transdifferentiation via Runx2[J/OL]. iScience, 2024, 27(2): 108766[2025-07-15]. .
[32]	LI W, FENG W, SU X, et al.. SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease[J/OL]. J. Clin. Invest., 2022, 132(1): e150051[2025-07-15]. .
[33]	HU C T, SHAO Y D, LIU Y Z, et al.. Oxidative stress in vascular calcification[J]. Clin. Chim. Acta, 2021, 519: 101-110.
[34]	ZHOU S, FANG X, XIN H, et al.. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway[J/OL]. PLoS ONE, 2013, 8(7): e68987[2025-07-15]. .
[35]	WANG Y, XIAO M, CAI F, et al.. Roxadustat ameliorates vascular calcification in CKD rats by regulating HIF-2α/HIF-1α[J]. Environ. Toxicol., 2024, 39(4): 2363-2373.
[36]	SPEER M Y, YANG H Y, BRABB T, et al.. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries[J]. Circ. Res., 2009, 104(6): 733-741.
[37]	LUO G, DUCY P, MCKEE M D, et al.. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein[J]. Nature, 1997, 386(6620): 78-81.
[38]	REYNOLDS J L, JOANNIDES A J, SKEPPER J N, et al.. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD[J]. J. Am. Soc. Nephrol., 2004, 15(11): 2857-2867.
[39]	KAPUSTIN A N, DAVIES J D, REYNOLDS J L, et al.. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization[J]. Circ. Res., 2011, 109(1): 1-12.
[40]	YAO Y, BENNETT B J, WANG X, et al.. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification[J]. Circ. Res., 2010, 107(4): 485-494.
[41]	WESTENFELD R, KRUEGER T, SCHLIEPER G, et al.. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial[J]. Am. J. Kidney Dis., 2012, 59(2): 186-195.
[42]	KETTELER M, BONGARTZ P, WESTENFELD R, et al.. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study[J]. Lancet, 2003, 361(9360): 827-833.
[43]	FUSARO M, NOALE M, VIOLA V, et al.. Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study[J]. J. Bone Miner. Res., 2012, 27(11): 2271-2278.
[44]	DE LA PUENTE-SECADES S, MIKOLAJETZ D, GAYRARD N, et al.. Vasoconstriction-inhibiting factor: an endogenous inhibitor of vascular calcification as a calcimimetic of calcium-sensing receptor[J]. Cardiovasc. Res., 2025, 121(3): 507-521.
[45]	AZPIAZU D, GONZALO S, GONZÁLEZ-PARRA E, et al.. Role of pyrophosphate in vascular calcification in chronic kidney disease[J]. Nefrologia, 2018, 38(3): 250-257.
[46]	FISH R S, KLOOTWIJK E, TAM F W K, et al.. ATP and arterial calcification[J]. Eur. J. Clin. Invest., 2013, 43(4): 405-412.
[47]	LOMASHVILI K A, GARG P, NARISAWA S, et al.. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification[J]. Kidney Int., 2008, 73(9): 1024-1030.
[48]	LENCEL P, DELPLACE S, PILET P, et al.. Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification[J]. Lab. Invest., 2011, 91(10): 1434-1442.
[49]	ZEBBOUDJ A F, SHIN V, BOSTRÖM K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells[J]. J. Cell. Biochem., 2003, 90(4): 756-765.
[50]	WESTENFELD R, SCHÄFER C, KRÜGER T, et al.. Fetuin-a protects against atherosclerotic calcification in CKD[J]. J. Am. Soc. Nephrol., 2009, 20(6): 1264-1274.
[51]	FEENSTRA L, REIJRINK M, PASCH A, et al.. Calciprotein particle counts associate with vascular remodelling in chronic kidney disease[J]. Cardiovasc. Res., 2024, 120(15): 1953-1966.
[52]	REYNOLDS J L, SKEPPER J N, MCNAIR R, et al.. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification[J]. J. Am. Soc. Nephrol., 2005, 16(10): 2920-2930.
[53]	HERMANS M M H, BRANDENBURG V, KETTELER M, et al.. Association of serum fetuin-a levels with mortality in dialysis patients[J]. Kidney Int., 2007, 72(2): 202-207.
[54]	HAMANO T, MATSUI I, MIKAMI S, et al.. Fetuin-mineral complex reflects extraosseous calcification stress in CKD[J]. J. Am. Soc. Nephrol., 2010, 21(11): 1998-2007.
[55]	HU B, WANG Y, YU L, et al.. Biomimetic wrinkled prebiotic microspheres with enhanced intestinal retention for hyperphosphatemia and vascular calcification[J/OL]. Sci. Adv., 2025, 11(3): eads5286[2025-07-15]. .
[56]	ZHANG D, ZHU Y, LI H, et al.. Associations of whole blood zinc levels with coronary artery calcification and future cardiovascular events in CKD patients[J]. Biol. Trace Elem. Res., 2024, 202(1): 46-55.
[57]	LOUVET L, BÜCHEL J, STEPPAN S, et al.. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells[J]. Nephrol. Dial. Transplant., 2013, 28(4): 869-878.
[58]	SALEM S, BRUCK H, BAHLMANN F H, et al.. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification[J]. Am. J. Nephrol., 2012, 35(1): 31-39.
[59]	LANZER P, SCHURGERS L, TWARDA-CLAPA A, et al.. Medial arterial calcification in ageing and disease: current evidence and knowledge gaps[J/OL]. Eur. Heart J., 2025: ehaf341[2025-07-15]. .
[60]	SHROFF R C, MCNAIR R, FIGG N, et al.. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis[J]. Circulation, 2008, 118(17): 1748-1757.
[61]	SCHLIEPER G, ARETZ A, VERBERCKMOES S C, et al.. Ultrastructural analysis of vascular calcifications in uremia[J]. J. Am. Soc. Nephrol., 2010, 21(4): 689-696.
[62]	KAPUSTIN A N, SHANAHAN C M. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles[J]. Trends Cardiovasc. Med., 2012, 22(5): 133-137.
[63]	刘昊, 李响. 冠状动脉疾病发病机制及治疗策略研究进展[J]. 生物技术进展, 2025, 15(2): 254-262.
	LIU H, LI X. Research progress on pathogenic mechanisms and treatment strategy of coronary artery disease[J]. Curr. Biotech., 2025, 15(2): 254-262.
[64]	BONASIO R, TU S, REINBERG D. Molecular signals of epigenetic states[J]. Science, 2010, 330(6004): 612-616.
[65]	LAUKKANEN M O, MANNERMAA S, HILTUNEN M O, et al.. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene[J]. Arterioscler. Thromb. Vasc. Biol., 1999, 19(9): 2171-2178.
[66]	MCDONALD O G, WAMHOFF B R, HOOFNAGLE M H, et al.. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo [J]. J. Clin. Invest., 2006, 116(1): 36-48.
[67]	ZHAI X, CAO S, WANG J, et al.. Carbonylation of Runx2 at K176 by 4-hydroxynonenal accelerates vascular calcification[J]. Circulation, 2024, 149(22): 1752-1769.
[68]	ALBINSSON S, SUAREZ Y, SKOURA A, et al.. microRNAs are necessary for vascular smooth muscle growth, differentiation, and function[J]. Arterioscler. Thromb. Vasc. Biol., 2010, 30(6): 1118-1126.
[69]	JONES P A, TAKAI D. The role of DNA methylation in mammalian epigenetics[J]. Science, 2001, 293(5532): 1068-1070.
[70]	LIU R, JIN Y, TANG W H, et al.. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity[J]. Circulation, 2013, 128(18): 2047-2057.
[71]	ZHUANG J, LUAN P, LI H, et al.. The Yin-Yang dynamics of DNA methylation is the key regulator for smooth muscle cell phenotype switch and vascular remodeling[J]. Arterioscler. Thromb. Vasc. Biol., 2017, 37(1): 84-97.
[72]	HILTUNEN M O, TURUNEN M P, HÄKKINEN T P, et al.. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions[J]. Vasc. Med., 2002, 7(1): 5-11.
[73]	JIANG J X, AITKEN K J, SOTIROPOULOS C, et al.. Phenotypic switching induced by damaged matrix is associated with DNA methyltransferase 3A (DNMT3A) activity and nuclear localization in smooth muscle cells (SMC)[J/OL]. PLoS ONE, 2013, 8(8): e69089[2025-07-15]. .
[74]	ROZENBERG J M, TESFU D B, MUSUNURI S, et al.. DNA methylation of a GC repressor element in the smooth muscle myosin heavy chain promoter facilitates binding of the Notch-associated transcription factor, RBPJ/CSL1[J]. Arterioscler. Thromb. Vasc. Biol., 2014, 34(12): 2624-2631.
[75]	NING Y, HUANG H, DONG Y, et al.. 5-Aza-2'-deoxycytidine inhibited PDGF-induced rat airway smooth muscle cell phenotypic switching[J]. Arch. Toxicol., 2013, 87(5): 871-881.
[76]	AZECHI T, SATO F, SUDO R, et al.. 5-aza-2'-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells[J]. J. Atheroscler. Thromb., 2014, 21(5): 463-476.
[77]	QIU P, LI L. Histone acetylation and recruitment of serum responsive factor and CREB-binding protein onto SM22 promoter during SM22 gene expression[J]. Circ. Res., 2002, 90(8): 858-865.
[78]	KEE H J, SKWON J, SHIN S, et al.. Trichostatin A prevents neointimal hyperplasia via activation of Krüppel like factor 4[J]. Vascul. Pharmacol., 2011, 55(5-6): 127-134.
[79]	QIU P, RITCHIE R P, GONG X Q, et al.. Dynamic changes in chromatin acetylation and the expression of histone acetyltransferases and histone deacetylases regulate the SM22alpha transcription in response to Smad3-mediated TGFbeta1 signaling[J]. Biochem. Biophys. Res. Commun., 2006, 348(2): 351-358.
[80]	BYON C H, JAVED A, DAI Q, et al.. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling[J]. J. Biol. Chem., 2008, 283(22): 15319-15327.
[81]	WILLEMS B A, FURMANIK M, CARON M M J, et al.. Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcification via SMAD-dependent BMP signalling[J/OL]. Sci. Rep., 2018, 8(1): 4961[2025-07-15]. .
[82]	TURNER M E, ROWSELL T S, LANSING A P, et al.. Vascular calcification maladaptively participates in acute phosphate homeostasis[J]. Cardiovasc. Res., 2023, 119(4): 1077-1091.
[83]	EL-ABBADI M M, PAI A S, LEAF E M, et al.. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin[J]. Kidney Int., 2009, 75(12): 1297-1307.
[84]	ZHANG K, ZHANG Y, FENG W, et al.. Interleukin-18 enhances vascular calcification and osteogenic differentiation of vascular smooth muscle cells through TRPM7 activation[J]. Arterioscler. Thromb. Vasc. Biol., 2017, 37(10): 1933-1943.
[85]	GLANCY B, BALABAN R S. Role of mitochondrial Ca²⁺ in the regulation of cellular energetics[J]. Biochemistry, 2012, 51(14): 2959-2973.
[86]	潘舟,胡克.线粒体功能障碍在缺氧性肺动脉高压中的作用[J].生物技术进展,2023,13(6):882-888.
	PAN Z, HU K. The role of mitochondrial dysfunction in hypoxic pulmonary hypertension[J]. Curr. Biotechnol., 2023, 13(6): 882-888.
[87]	IZZO V, BRAVO-SAN P J M, SICA V, et al.. Mitochondrial permeability transition: new findings and persisting uncertainties[J]. Trends Cell Biol., 2016, 26(9): 655-667.
[88]	BAI Y, ZHANG J, XU J, et al.. Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells[J]. Biomed. Rep., 2015, 3(4): 593-597.
[89]	MA W Q, SUN X J, WANG Y, et al.. Restoring mitochondrial biogenesis with metformin attenuates β-GP-induced phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of PDK4/oxidative stress-mediated apoptosis[J]. Mol. Cell. Endocrinol., 2019, 479: 39-53.
[90]	ZHU Y, JI J J, YANG R, et al.. Lactate accelerates calcification in VSMCs through suppression of BNIP3-mediated mitophagy[J]. Cell. Signal., 2019, 58: 53-64.
[91]	GIACHELLI C M. The emerging role of phosphate in vascular calcification[J]. Kidney Int., 2009, 75(9): 890-897.
[92]	HSU Y J, HSU S C, HUANG S M, et al.. Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling[J]. J. Vasc. Surg., 2015, 62(1): 210-221.
[93]	DAI X Y, ZHAO M M, CAI Y, et al.. Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release[J]. Kidney Int., 2013, 83(6): 1042-1051.
[94]	FRAUSCHER B, KIRSCH A H, SCHABHÜTTL C, et al.. Autophagy protects from uremic vascular media calcification[J/OL]. Front. Immunol., 2018, 9: 1866[2025-07-15]. .
[95]	BRAAKMAN I, HEBERT D N. Protein folding in the endoplasmic reticulum[J/OL]. Cold Spring Harb. Perspect. Biol., 2013, 5(5): a013201[2025-07-15]. .
[96]	RAO R V, BREDESEN D E. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration[J]. Curr. Opin. Cell Biol., 2004, 16(6): 653-662.
[97]	DUAN X, ZHOU Y, TENG X, et al.. Endoplasmic reticulum stress-mediated apoptosis is activated in vascular calcification[J]. Biochem. Biophys. Res. Commun., 2009, 387(4): 694-699.
[98]	DUAN X H, CHANG J R, ZHANG J, et al.. Activating transcription factor 4 is involved in endoplasmic reticulum stress-mediated apoptosis contributing to vascular calcification[J]. Apoptosis, 2013, 18(9): 1132-1144.
[99]	MASUDA M, MIYAZAKI-ANZAI S, LEVI M, et al.. PERK-eIF2α-ATF4-CHOP signaling contributes to TNFα-induced vascular calcification[J/OL]. J. Am. Heart Assoc., 2013, 2(5): e000238[2025-07-15]. .
[100]	MIYAZAKI-ANZAI S, MASUDA M, DEMOS-DAVIES K M, et al.. Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification[J/OL]. J. Am. Heart Assoc., 2014, 3(3): e000949[2025-07-15]. .
[101]	MASUDA M, TING T C, LEVI M, et al.. Activating transcription factor 4 regulates stearate-induced vascular calcification[J]. J. Lipid Res., 2012, 53(8): 1543-1552.
[102]	KELLER M, SCHLEINITZ D, FÖRSTER J, et al.. THOC5 a novel gene involved in HDL-cholesterol metabolism[J]. J. Lipid Res., 2013, 54(11): 3170-3176.
[103]	KOVACIC J C, MORENO P, HACHINSKI V, et al.. Cellular senescence, vascular disease, and aging: Part 1 of a 2-part review[J]. Circulation, 2011, 123(15): 1650-1660.
[104]	KOVACIC J C, MORENO P, NABEL E G, et al.. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly[J]. Circulation, 2011, 123(17): 1900-1910.
[105]	TONELLI M, CURHAN G, PFEFFER M, et al.. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality[J]. Circulation, 2009, 120(18): 1784-1792.
[106]	LONDON G M. Bone-vascular cross-talk[J]. J. Nephrol., 2012, 25(5): 619-625.
[107]	MUTELIEFU G, SHIMIZU H, ENOMOTO A, et al.. Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress[J]. Am. J. Physiol. Cell Physiol., 2012, 303(2): 126-134.
[108]	OHYAMA Y, KURABAYASHI M, MASUDA H, et al.. Molecular cloning of rat klotho cDNA: markedly decreased expression of klotho by acute inflammatory stress[J]. Biochem. Biophys. Res. Commun., 1998, 251(3): 920-925.
[109]	KURO O M. Klotho as a regulator of oxidative stress and senescence[J]. Biol. Chem., 2008, 389(3): 233-241.
[110]	LIU F, WU S, REN H, et al.. Klotho suppresses RIG-I-mediated senescence-associated inflammation[J]. Nat. Cell Biol., 2011, 13(3): 254-262.
[111]	SHILOH Y, ZIV Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more[J]. Nat. Rev. Mol. Cell Biol., 2013, 14(4): 197-210.
[112]	D'ADDA DI FAGAGNA F, REAPER P M, CLAY-FARRACE L, et al.. A DNA damage checkpoint response in telomere-initiated senescence[J]. Nature, 2003, 426(6963): 194-198.
[113]	TOUSSAINT O, ROYER V, SALMON M, et al.. Stress-induced premature senescence and tissue ageing[J]. Biochem. Pharmacol., 2002, 64(5-6): 1007-1009.
[114]	LI X, LIU A, XIE C, et al.. The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair[J]. Kidney Int., 2024, 105(1): 115-131.
[115]	LIU Y, DROZDOV I, SHROFF R, et al.. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells[J]. Circ. Res., 2013, 112(10): 99-109.
[116]	RODIER F, PCOPPÉ J, PATIL C K, et al.. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion[J]. Nat. Cell Biol., 2009, 11(8): 973-979.
[117]	FADINI GP, RATTAZZI M, MASTSUNOTO T, et al.. Emerging role of circulating calcifying cells in the bone-vascular axis[J].Circulation, 2012, 125(22): 2772-2781.
[118]	GORDON L B, KLEINMAN M E, MILLER D T, et al.. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome[J]. Proc. Natl. Acad. Sci. USA, 2012, 109(41): 16666-16671.
[119]	UGALDE A P, RAMSAY A J, DE LA ROSA J, et al.. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53[J]. EMBO J., 2011, 30(11): 2219-2232.
[120]	ALESUTAN I, RAZAZIAN M, LUONG T T D, et al.. Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification[J]. Kidney Int., 2024, 106(4): 611-624.

慢性肾脏病患者血管钙化的机制研究

Mechanistic Insights into Vascular Calcification in Chronic Kidney Disease Patients

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 120

相关文章 0

编辑推荐

Metrics

本文评价